NYSE Amex Accepts China Shenghuo's Compliance Plan for Continu... ( KUNMING China June 8 Asia-FirstCa...)

NYSE Amex Accepts China Shenghuo's Compliance Plan for Continued Listing

Date:6/8/2009

KUNMING, China, June 8 /PRNewswire-Asia-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. (NYSE Amex Equities: KUN) ("China Shenghuo" or the "Company"), which is engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products in the People's Republic of China ("PRC"), today announced that the NYSE Amex LLC (the "NYSE Amex" or "Exchange") has accepted the Company's plan of compliance for continued listing.

On February 10, 2009, the Company received notice from the NYSE Amex Staff indicating that the Company is below certain of the Exchange's continued listing standards due to the Company's failure to hold an annual meeting of stockholders in 2008, as set forth in Section 704 of the NYSE Amex Company Guide. The Company submitted a plan of compliance to the Exchange by February 17, 2009. The plan was accepted by the Exchange and a listing extension was granted until August 11, 2009. The Company will be subject to periodic review by Exchange Staff during the extension period. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the extension period could result in the Company being delisted from the Exchange.

The Company will hold its annual meeting of stockholders at 10:00 A.M. Beijing Time on Monday, June 15, 2009. The Company believes that holding the annual meeting will satisfy the deficiency, and the Company intends to hold future annual meetings of stockholders on an annual basis, in accordance with the Exchange's listing standards.

"We are pleased with the decision by the Exchange to continue our listing and look forward to meeting the business goals established by the Company in our plan," said Mr. Gui Hua Lan, Chief Executive Officer of China Shenghuo.

About China Shenghuo

Founded in 1995, China Shenghuo is a speci
'/>"/>

SOURCE China Shenghuo Pharmaceutical Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. NYSE Amex LLC Accepts Plan of Compliance of The Quantum Group, Inc.
2. United States Patent and Trademark Office Accepts CoolTouch's Re-examination Request for Cynosure '873 Patent
3. NYSE Amex Accepts Interleukin Genetics Plan to Meet Continued Listing Standards
4. Gamma Pharmaceuticals Accepts PO From Leading St. Louis Missouri Distributor. Order Valued up to $850,000 Retail Market Value
5. FDA Accepts Nuvos Resubmission For Pennsaid(R)
6. ROXRO Announces FDA Accepts for Review NDA for ROX-888 for the Management of Acute Moderate to Severe Pain
7. Andre Konski, M.D., M.B.A., Accepts Radiation Oncology Position at Wayne State University and the Karmanos Cancer Institute
8. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
9. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
10. FDA Accepts Gentas NDA Amendment as Complete Response for Genasense(R) Treatment of Chronic Lymphocytic Leukemia
11. Partnering With MyPyramid: NUTRIKIDS Accepts the Challenge to Help Families Step Up to Healthier Living

Post Your Comments:

(Date:12/17/2009)... New report offers a revealing portrait of the nearly one-in-three American ... ... Arlington, VA (PRWEB) December 17, 2009 -- The National Alliance on ... U.S. 2009 , which offers a revealing portrait of the nearly ... ,The study is based on interviews with 1,480 caregivers chosen at ...

(Date:12/17/2009)... Substance Specific Neurological Stress Reduction Therapy or NSRTSM is found ... chronic conditions such as allergies, asthma, migraines, chronic fatigue and ... practices throughout the country are using this holistic therapy including ... ... Allentown, PA (Vocus) December 16, 2009 ...

(Date:12/16/2009)... If proposed health care legislation is ... employer-based insurance system. Approximately 18.4 million Californians and ... rely upon employer-based insurance for their health care ... of reform legislation entail specific requirements for employer-based ... work for firms that currently comply with most ...

(Date:12/16/2009)... CHEVY CHASE, Md., Dec. 16 New ... capital firm, today announced that one of its ... definitive agreement to be acquired by Ethicon, Inc., ... transaction for approximately $785 million (net of estimated ... medical technology company dedicated to designing, developing and ...

(Date:12/16/2009)... Dec. 16 Allscripts (Nasdaq: MDRX ... financial results for the three and six months ... opens on Monday, January 11, 2010. Allscripts management ... discuss the company,s earnings and other information at ... ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, Allscripts ...

Breaking Medicine News(10 mins):Health News:NAMI Applauds New Report on Caregiving 2 Health News:NAMI Applauds New Report on Caregiving 3 Health News:BioVeda Health and Wellness Center of Allentown, PA Announces Its Grand Opening 2 Health News:BioVeda Health and Wellness Center of Allentown, PA Announces Its Grand Opening 3 Health News:BioVeda Health and Wellness Center of Allentown, PA Announces Its Grand Opening 4 Health News:BioVeda Health and Wellness Center of Allentown, PA Announces Its Grand Opening 5 Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 2 Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 3 Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2 Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3 Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2 Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3 Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4

[0] NAMI Applauds New Report on Caregiving [0] BioVeda Health and Wellness Center of Allentown, PA Announces Its Grand Opening [1] How National Health Reform Proposals Would Affect Employer-Based Plans in California [0] NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon [0] Allscripts to Announce Second Quarter Fiscal 2010 Results

... annual HMO,report card released today by the Schwarzenegger ... not allow consumers to accurately evaluate HMO,quality or ... medical failures and illegal behavior that is rampant ... Taxpayer and Consumer Rights,(FTCR)., FTCR noted that ...

... The National Association of,Dental Plans (NADP) calls on ... Children,s Health Insurance Program (CHIP).,Specifically, NADP urges prompt action ... passed CHIP reauthorization bill., In letters to congressional ... -- Dental services should be a mandatory ...

... (Mo.) issued the following statement today after the House,sustained ... Insurance Program (SCHIP) to children from families who,earn as ... to a close what,s been a disappointing chapter on,SCHIP, ... scoring,political points, and none of it toward working with ...

... Oct. 18 Omnicell, Inc.,(Nasdaq: OMCL ), a ... announced results for its third quarter ended September,30, 2007. ... 2007 totaled $55.2,million, up $3.3 million or 6.4% from ... million or 33.8% from the third quarter of 2006. ...

... EDITOR,S PICK: New links in the cystic fibrosis chain uncover ... inherited disease caused by mutations in the CFTR gene. Each ... lungs. New evidence generated in vitro by Vojo Deretic and ... Albuquerque, has provided insight into the mechanisms by which one ...

... are kept awake by a variety of symptoms, survey found ... symptoms such as acid reflux, the less typical symptoms of ... choking, snoring, sore throat, and chest pain -- can cause ... , The poll of 701 GERD patients found that sleep ...

State's HMO 'Report Card' Fails in Meaningful Evaluation of Health Care Quality and Ignores Affordability NADP Calls on Congress and the White House to Work Together to Cover Children's Dental Health Blunt: House Sustains President's Veto, Now Let's Get to Work on Genuine Solution Omnicell Reports Strong Q3 Revenue and Profit Growth JCI table of contents: Oct. 18, 2007 Chronic Reflux Often Leads to Sleepless Nights

(Date:12/16/2009)... /PRNewswire/ -- Sanofi Pasteur, the ... today that it has entered into an ... develop and commercialize its prophylactic vaccine against ... aureus or MRSA. MRSA are responsible ... referred to as multidrug-resistant Staphylococcus aureus ...

(Date:12/16/2009)... ARBOR, Mich., Dec. 16 GlaxoSmithKline plc ... Corporation today announced an exclusive licensing agreement in ... (OTC) use of NB-001, a novel, patented compound ... cold sores. Developed by NanoBio, NB-001 provides significant ... sores, herpes labialis . ,, Cold ...

(Date:12/16/2009)... CORALVILLE, Iowa, Dec. 16 Vivakor, ... a Business Development agreement with Baker Consulting ... affiliate group, Kyouko Group, Inc. out of ... retained by Vivakor to assist with business ... its recently reported acquisition strategy. Specifically, Baker ...

Breaking Medicine Technology:Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 2 Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 3 Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 4 GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment 2 Vivakor Signs Business Development Agreement With Baker Consulting 2 High School Sports Put Players at Risk for Severe Injuries 56218 1 High School Sports Put Players at Risk for Severe Injuries 56218 2 Swine Flu Poses Risk to Kids With Neurological Conditions 56216 1 Swine Flu Poses Risk to Kids With Neurological Conditions 56216 2 Swine Flu Poses Risk to Kids With Neurological Conditions 56216 3 Swine Flu Poses Risk to Kids With Neurological Conditions 56216 4 Spherix Incorporated to Present at the Rodman 26 Renshaw 11th Annual Healthcare Conference 13847 1 Spherix Incorporated to Present at the Rodman 26 Renshaw 11th Annual Healthcare Conference 13847 2

[0] Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections [0] GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment [0] Vivakor Signs Business Development Agreement With Baker Consulting

... Micromet, Inc.,(Nasdaq: MITI ), a ... treatment of cancer, inflammation and autoimmune,diseases, presented ... Association for,Cancer Research (AACR) in San Diego, ... (Herceptin(R); Genentech, Roche),cetuximab (Erbitux(R); Bristol-Myers Squibb, Imclone, ...

... Physician scientists at,the Texas Heart Institute (THI) ... the world,s first clinical trial to treat heart ... to promote better healing and to,prevent congestive heart ... Almost six million Americans have congestive heart ...

Other Medicine Technology:Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 2 Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 3 Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 4 Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 5 Texas Heart(R) Institute at St. Luke's Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type 2 Texas Heart(R) Institute at St. Luke's Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type 3

Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies Texas Heart(R) Institute at St. Luke's Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type

... of flexible lighting products. The first is ... different sizes 5", 10", and 15" (refers ... light). These lights are for use in ... ,The second group of flexible lights is ...

... two groups of flexible lighting products. The ... in three different sizes 5", 10", and ... of the light). These lights are for ... needed., ,The second group of flexible ...

... standby switch maintains power to the instrument without generating ... of 50 Hz separated by .75 s; repeats every ... Hz (2 pulses/s) , Tetanus: 50 Hz (50 ... pulses/2 s; repeats every 10 s , Output Current: ...

Anesthesia Associates Model 100 Compact Peripheral Nerve Stimulator, incorporates the latest state-of-the-art electronics with solid state cicuitry to ensure trouble-free operation and extended batte...

Medicine Products:

Lighted Orotracheal Stylet - Sterile Surch-Lite™ Flexible Light - 5" Non-Sterile Digistim 3 Plus Nerve Stimulator Compact Peripheral Nerve Stimulator

NYSE Amex Accepts China Shenghuo's Compliance Plan for Continu...( KUNMING China June 8 Asia-FirstCa...),Health